|
- rVSV-ZEBOV vaccine - Wikipedia
Recombinant vesicular stomatitis virus–Zaire Ebola virus (rVSV-ZEBOV), also known as Ebola Zaire vaccine live and sold under the brand name Ervebo, is an Ebola vaccine for adults that prevents Ebola caused by the Zaire ebolavirus
- GRADE: rVSVΔG-ZEBOV-GP Ebola vaccine for persons in the U. S. population . . .
On February 26, 2020, the Advisory Committee on Immunization Practices (ACIP) recommended pre-exposure vaccination with rVSVΔG-ZEBOV-GP vaccine for adults aged 18 years or older in the United States population who are at potential risk of exposure to EBOV: Previously, ACIP had no recommendations for the use of vaccines to prevent EVD
- Ebola Vaccines | NIAID: National Institute of Allergy and Infectious . . .
The rVSV-ZEBOV vaccine uses a genetically engineered version of vesicular stomatitis virus (VSV), an animal virus that primarily affects cattle, to carry an Ebola virus gene insert Experts at the Public Health Agency of Canada originally developed the vaccine, which is now licensed to Merck
- Ebola virus vaccines - World Health Organization (WHO)
The rVSV-ZEBOV elicits innate immune responses and adaptive immune responses within 7–14 days Merck updated the clinical safety profile of the investigational rVSV-ZEBOV-GP (V920) vaccine
- A Recombinant Vesicular Stomatitis Virus Ebola Vaccine
We conducted two phase 1, placebo-controlled, double-blind, dose-escalation trials of an rVSV-based vaccine candidate expressing the glycoprotein of a Zaire strain of Ebola virus (ZEBOV)
- Assessing the real-world effectiveness of the rVSV-ZEBOV vaccine
Data from 26 438 individuals were analysed, of whom 1273 were Ebola virus disease-positive rVSV-ZEBOV was highly effective, with an overall effectiveness of 84% (95% credible interval 70–92) against Ebola virus disease 10 days or more post vaccination
- rVSVΔG-ZEBOV-GP (also designated V920) recombinant vesicular stomatitis . . .
The rVSV-ZEBOV vaccine is a live, replication competent vector in which the VSV glycoprotein (G) gene is replaced with the glycoprotein (GP) gene of ZEBOV Multiple copies of GP are expressed and assembled into the viral envelope responsible for inducing protective immunity
- Evidence to Recommendations for rVSVΔG-ZEBOV-GP Ebola vaccine for . . .
Pre-exposure vaccination with rVSVΔG-ZEBOV-GP vaccine is recommended for adults 18 years of age or older in the U S population who are responding to an outbreak of EVD due to Ebola virus (species Zaire ebolavirus)
|
|
|